LXRX vs REG · rev $21.8M vs P/E 34, rev $1.45B
Lexicon Pharmaceuticals Inc (LXRX) versus Regency Centers Corporation (REG) — a side-by-side from cached financials, not a winner call.
Lexicon Pharmaceuticals Inc (LXRX) is a biotechnology company listed on US.
Regency Centers Corporation (REG) is a reit - retail company listed on US.
Latest reported LXRX revenue for 2026-06-30 was $21.8M. Net income was -$32.8M. Revenue was up 3.3% from 2026-03-31 to 2026-06-30. LXRX currently screens at market cap $327.2M.
Latest reported REG revenue for 2024-12-31 was $1.45B. Net income was $409.8M. Revenue was up 9.9% from 2023-12-31 to 2024-12-31. REG currently screens at market cap $12.93B and trailing P/E 33.5.
LXRX currently screens at market cap $327.2M. REG currently screens at market cap $12.93B and trailing P/E 33.5.
Not investment advice. Open the LXRX and REG stock pages for the full models.
Not investment advice.